Pharmather Holdings Ltd C.PHRM

PHRM

[moneywagon]

GOOOD MORNING PHRM!! nothing to bullshyte about here!! I am an ole ole dawg that played the swings with rvv for over 3years and I made wagons upon wagons full of rvv money! $$$$$ aka moneynorthbound!! Now that was a few years ago. I always visit the rvv bb cuz she is like an ole girlfriend you can't stop smiling about $$$$ lol.

NOW, PHRM here has a direct path...a duplicate CARBON photo copy of rvv. 
The same PLAYERS insiders!!
When I owned rvv, I lived in Woodbridge, right around the corner from rvv head office!

I would throw a penny in the parking lot out my window lol when I drove past and as an investor I would absolutely drop in and see how my money was progressing. 

Never fall in love with a stock....coles foot notes on investing rule number one!!
I take sector momentum very seriously when pulling the trigger on a buy!

Health sector is still in FULL SWING and just watch Canada is going to go BACK INTO LOCK DOWN this late Spring & Summer!!

Ba2 locked down China 6 th wave and now its has locked down INdia. 
SO....GET READY for all those summer airplane flights to get cancelled!! 

I play with 350K on TD platform and 200K on BMO platform, 17 egg baskets, I cast my net wider than your pockets will ever hold Godfadder!!
The fact that PHRM even got my money is a surprise to me BUT BUT the sp has been beaten up like an bad day for Avon Lady lay cryin in da ditch ahhaha lmfaso so how the fuk can moneywagon NOT put some gas money into this 10K.
I still got powder if they pressure sp to single digits!! lol :>))

So, stop the bullsyte and post something worthy peeps!!!

LET' GET READY TO RUMBLE UP or DOWN. hahaha no way sp can stay down here with those successful clinical results....now moving into phase 3.
 
This is a walk in the park for the Captain of this ship Fabio Chianelli!!
rvv was his first baby and he walked down every FDA a$$ kissing permit needed to get to product revenue. 

Nothing has been posted as to why the sp has been beaten so badly I just know its way oversold and mei money is here to catch the swing up! 

Best read this article again cuz that is WAY MORE entertaining/informative than me, as you can actually contribute posting about PHRM than bullsyte attacks against mei!!

• Home
• Psychedelics
• PharmaTher and Revive Therapeutics: The Latest Psychedelic Partnership

 VIDEOPSYCHEDELICS

PharmaTher and Revive Therapeutics: The Latest Psychedelic Partnership

By Aaron Wolko  On Nov 19, 2020

 

 Share

When PharmaTher (CNSX: PHRM) and Revive Therapeutics (CNSX: RVV), two psychedelic companies, entered into a research collaboration yesterday, The Dales Report decided to dig deeper into the partnership, and it’s potential impact on the respective companies and shareholder value. What stands out about the transaction is the focus each maintains on their various fields. 

Mergers and exclusive partnerships in any public industry usually make news, but when younger players in nascent sectors start teaming up, it’s usually worth taking a closer look. Take AusCann as an example. You probably haven’t heard of them, but you definitely know the company with whom they signed a stock swap back in 2016, Canopy Growth. As a result, in 2018 when Canopy started reaching multi billion dollar valuations, AusCann soared to ~$600M AUD market cap, primarily based off their partnership and stock options in Canopy. When analyzing this transaction in retrospect, what’s most striking is where Canopy was at the time, a relatively unknown company with a share price of 35c. Now they’re the behemoth of the cannabis industry and anyone with merely peripheral knowledge in the sector would consider them a household name.

PharmaTher is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Unique to their IP portfolio is company’s attempt at drug-repurposing using an artificial intelligence platform call panaceAI. This tool combines multilayered processes for integrating millions of data points and performing machine learning to discover new uses of psychedelic-based drugs. The company was founded with a focus on repurposing psychedelic pharmaceuticals like ketamine, for FDA approval to treat disorders of the brain and nervous system, including Parkinson’s disease, depression and pain. 

During an interview with CSE TV in June of this year, CEO Fabio Chianelli made clear his intentions to “have research agreements in place with well-known academic institutions to help conduct these studies”, and he’s made good on that promise. Last month the company announced they had entered into an exclusive license agreement with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson’s disease. PharmaTher will seek FDA approval of an investigational new drug application to conduct a Phase II clinical study. 

Adding to their pipeline, the company went on to file an application with the FDA to receive Orphan Drug Designation for ketamine to treat the painful symptoms of shingles. The global market is expected to be valued at ~$1B USD in the next half decade. This is one of the first such moves in a strategic plan to treat many rare disorders using psychedelics, that haven’t been researched en mass in 50 years. 

He went on to hint at collaborations with other players in the space citing his firm belief that “no one’s a competitor, we’re all partners trying to build up an industry and validate that in any way we can contribute”. In line with that statement, the company yesterday announced that they had entered into an exclusive research collaboration agreement with Revive Therapeutics, to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds. 

Revive Therapeutics, predominantly a biotech company, has recently explored the use of psychedelic compounds in the treatment of cancer and mental disorders. As of yesterday, Revive will have access to the PharmaTher discovery AI platform, panaceAI, which will assist them in identifying numerous positive outcomes for these natural chemicals and the millennia old diseases the scientific community aims to treat. 

The joining of teams comes as no surprise to analysts in the sector, as PharmaTher’s CEO founded and managed Revive for almost a decade, stepping down from his formal position as President in late 2019. The collaboration will give Revive the exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI psychedelic discovery AI platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology.

So while PharmaTher focuses on ketamine therapy, using a microneedle technology in the form of a patch, which they acquired the rights to from UCLA recently, Revive will focus on psilocybin and it’s effect on an array of medical issues. Together, the team may lead the way in how wide reaching research is conducted in the sector, making up for half a century of lost time.

[Godfather]

With all of that buying power, you would think that you would be able to buy more than a couple thousand shares of this stock. Especially, with all of the upside you feel this company has. That is, if it's not imaginary buying power. LOL

[moneywagon]

I got warrant certificates at NOB with CNC wings...lol  that expire this week so sorry bro bigger gains their for now$$$ yummmy gains. I just took a wee cookie here, shyte there are a million poker tables out there right now to sit at, you know that Godfadder. I repeat the fact that PHRM even got my money was a fluke of over sold alert!! simple dimple. 

[Godfather]

Just the fact that you feel the need to brag about your imaginary investment accounts, and your childish posting style is a dead giveaway, that you are a fraud. Anybody, that has a serious amount of money to invest, does not buy $1200.00 of any stock. Simple dimple.